Overview

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

Status:
COMPLETED

Trial end date:
2025-08-19

Target enrollment:

Participant gender:

Summary

This study includes extended CD34+ profiling on the apheresis product of multiple myeloma patients undergoing standard-of-care quad-induction followed by motixafortide + G-CSF mobilization, and in addition, assesses the pharmacodynamics (PD) of motixafortide following "standard" (\~12 hours) vs "early" (\~16 hours) dosing. The investigators hypothesize that quad-induction may alter the stem cell subsets within the mobilized graft. The investigators further hypothesize that standard and early dosing strategies will result in comparable mobilization and stem cell collection rates.

Phase:

PHASE1

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

Arvrmid Pharma
BioLineRx, Ltd.

Treatments:

4-fluorobenzoyl-TN-14003
Granulocyte Colony-Stimulating Factor